CTNM · Contineum Therapeutics Inc. Class A Common Stock
View on chartInsiders & Stakes
| Versant Venture Capital VI, L.P. 10% Owner | ▼ Sell | Other | 148,312 Shares held | 4/9/2024 | View profile |
| Daniel S. Lorrain Chief Scientific Officer | ▼ Sell | Open Market | 135,202 Shares held | 7/9/2026 | View profile |
| Carmine N. Stengone CEO and President | ▼ Sell | Open Market | 17,217 Shares held | 9/8/2026 | View profile |
| Huhn Stephen L. CMO & Sr VP, Clinical Dev. | ▲ Buy | Option Exercise | 12,800 Shares held | 8/13/2024 | View profile |
| Tim Watkins CMO & Head of Development | ▼ Sell | Open Market | 8,961 Shares held | 6/30/2026 | View profile |
Transaction History
| Carmine N. Stengone | ▲ Buy | Option Exercise | 2,500 | $3K | 9/8/2026 |
| Carmine N. Stengone | ▼ Sell | Open Market | 2,500 | $41K | 9/8/2026 |
| Carmine N. Stengone | ▲ Buy | Option Exercise | 2,500 | $3K | 8/3/2026 |
| Carmine N. Stengone | ▼ Sell | Open Market | 2,500 | $40K | 8/3/2026 |
| Daniel S. Lorrain | ▲ Buy | Option Exercise | 25 | $25 | 7/9/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 25 | $400 | 7/9/2026 |
| Daniel S. Lorrain | ▲ Buy | Option Exercise | 1,015 | $1K | 7/8/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 1,015 | $16K | 7/8/2026 |
| Carmine N. Stengone | ▲ Buy | Option Exercise | 2,500 | $3K | 7/8/2026 |
| Carmine N. Stengone | ▼ Sell | Open Market | 2,500 | $40K | 7/8/2026 |
| Daniel S. Lorrain | ▲ Buy | Option Exercise | 4,183 | $4K | 7/1/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 5,852 | $92K | 7/1/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 2,501 | $41K | 7/1/2026 |
| Daniel S. Lorrain | ▲ Buy | Option Exercise | 28,826 | $29K | 6/30/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 28,826 | $462K | 6/30/2026 |
| Tim Watkins | ▲ Buy | Option Exercise | 10,833 | $49K | 6/30/2026 |
| Tim Watkins | ▼ Sell | Open Market | 10,833 | $174K | 6/30/2026 |
| Carmine N. Stengone | ▲ Buy | Option Exercise | 7,500 | $8K | 6/30/2026 |
| Carmine N. Stengone | ▲ Buy | Option Exercise | 2,500 | $3K | 6/30/2026 |
| Carmine N. Stengone | ▼ Sell | Open Market | 10,000 | $160K | 6/30/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 4,170 | $55K | 6/1/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 3,870 | $51K | 5/1/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 300 | $4K | 5/1/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 4,170 | $56K | 4/6/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 4,170 | $63K | 3/2/2026 |
| Tim Watkins | ▲ Buy | Option Exercise | 3,611 | $16K | 3/2/2026 |
| Tim Watkins | ▼ Sell | Open Market | 3,611 | $54K | 3/2/2026 |
| Carmine N. Stengone | ▲ Buy | Option Exercise | 2,700 | $3K | 2/25/2026 |
| Carmine N. Stengone | ▼ Sell | Open Market | 2,700 | $43K | 2/25/2026 |
| Daniel S. Lorrain | ▲ Buy | Option Exercise | 3,824 | $4K | 2/25/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 3,824 | $61K | 2/25/2026 |
| Carmine N. Stengone | ▲ Buy | Option Exercise | 4,400 | $6K | 2/24/2026 |
| Carmine N. Stengone | ▼ Sell | Open Market | 4,400 | $70K | 2/24/2026 |
| Daniel S. Lorrain | ▲ Buy | Option Exercise | 4,300 | $4K | 2/24/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 4,300 | $69K | 2/24/2026 |
| Daniel S. Lorrain | ▲ Buy | Option Exercise | 100 | $101 | 2/19/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 100 | $2K | 2/19/2026 |
| Carmine N. Stengone | ▲ Buy | Option Exercise | 400 | $504 | 2/11/2026 |
| Carmine N. Stengone | ▼ Sell | Open Market | 400 | $6K | 2/11/2026 |
| Daniel S. Lorrain | ▲ Buy | Option Exercise | 400 | $404 | 2/11/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 400 | $6K | 2/11/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 3,000 | $44K | 2/3/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 1,170 | $18K | 2/3/2026 |
| Tim Watkins | ▲ Buy | Option Exercise | 3,611 | $16K | 1/28/2026 |
| Tim Watkins | ▼ Sell | Open Market | 2,800 | $39K | 1/28/2026 |
| Tim Watkins | ▼ Sell | Open Market | 811 | $12K | 1/28/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 3,670 | $38K | 1/5/2026 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 500 | $6K | 1/5/2026 |
| Tim Watkins | ▲ Buy | Option Exercise | 3,611 | $16K | 12/29/2025 |
| Tim Watkins | ▼ Sell | Open Market | 3,611 | $44K | 12/29/2025 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 4,170 | $51K | 12/23/2025 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 1,010 | $16K | 11/25/2024 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 6,091 | $100K | 11/18/2024 |
| Daniel S. Lorrain | ▼ Sell | Open Market | 99 | $2K | 11/18/2024 |
| Huhn Stephen L. | ▲ Buy | Option Exercise | 12,800 | $13K | 8/13/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 148,312 | — | 4/9/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 391,785 | — | 4/9/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Other | 2,531 | — | 4/9/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
CTNM Depressed After Phase 2 Miss
Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.
CTNM Depressed After Phase 2 Miss. Contineum Therapeutics recently announced that its depression drug, developed with Johnson & Johnson, failed to meet its primary goal in a Phase 2 trial. This clinical setback is a significant event for the company, as it raises questions about the future development timeline and potential commercialization of the asset. The stock is currently trading near its 52-week low, reflecting the market's reaction to this negative data.